Study of Capecitabine In Patients With Solid Tumors

Solid Tumors Clinical Trial

Official title:

A Phase I Study of Capecitabine In Patients With Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00697502
• Other study ID #: PG03/32/06
• Status: Completed
• Phase: Phase 1
• First received: June 11, 2008
• Last updated: October 31, 2012
• Start date: May 2007
• Est. completion date: May 2012

Study information

• Verified date: October 2012
• Source: National University Hospital, Singapore
• Contact: n/a
• Is FDA regulated: No
• Health authority: Singapore: Domain Specific Review Boards
• Study type: Interventional

Clinical Trial Summary

Hypothesis:

Patients with TYMS 2R/2R or 2R/3R appear to be more sensitive to fluoropyrimidines, conferring a higher risk of grade 3-4 fluoropyrimidine related toxicity and a higher response rate compared with 3R/3R. The genotype 3R/3R is more common in East Asia and is associated with greater tolerability to fluoropyrimidine as measured by lower toxicity but also lower response rates. As sensitivity to fluoropyrimidine appears to be affected by TYMS genotype, we hypothesise that patients with TYMS 3R/3R are more tolerant to standard doses of capecitabine and require higher doses to overcome fluoropyrimidine resistance. We designed this study to develop TYMS genotype specific dosing of capecitabine.

Aims:

1. To determine the maximal tolerated dose (MTD) of capecitabine twice a day for two weeks followed by one week rest period (intermittent schedule) in patients with the advanced/ and or metastatic cancer based on TYMS genotype.

2. To determine a suitable phase II dose of intermittent schedule capecitabine.

3. To determine the safety and toxicity of this regimen.

4. To perform plasma pharmacokinetics of capecitabine.

5. To determine the relationship between genes of relevance in the fluoropyrimidine pathway with pharmacokinetics and toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Cytologically or histologically confirmed advanced or metastatic non- hematologic malignancy that had failed previous therapies or cancer for which there are no standard treatment options.

2. Presence of at least one uni-dimensional measurable lesion as defined by the RECIST criteria.

3. Required genotype characteristics:

• Group 1: TSER genotype 2R/2R or 2R/3R

• Group 2: TSER genotype 3R/3R

4. Able to swallow capsules

5. Age>=18 years

6. Kanorfsky performance status of at least 70% or ECOG performance status <2 (Appendix A)

7. Life expectancy of at least 3 months

8. Hb >=9 g/dL

9. ANC >=1.5 x 10^9/L

10. Platelet count >=100 x 10^9/L.

11. Total bilirubin and serum creatinine <=1.5x upper limits of normal reference range (ULN)

12. Alkaline phosphatase, AST/ALT levels <=2.5x upper limit of normal. If hepatic metastases are present, these parameters could be <=10x the ULN.

13. Women of reproductive age and men must agree to practice effective contraception during the entire study period. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child- bearing potential. Females with childbearing potential must have a negative serum pregnancy test within 7days prior to study enrolment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

14. Signed written informed consent

Exclusion Criteria:

1. Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within 28 days prior to study drug administration (6 weeks for mitomycin or nitroureas) and not recovered.

2. Patients who have not recovered from major surgery

3. Any woman pregnant or lactating.

4. Known CNS metastases

5. Renal impairment with a creatinine clearance <=50mL/min (as calculated according to Cockcroft and Gault formula) or serum creatinine > ULN

6. Clinically significant cardiac disease, eg. Congestive cardiac failure, symptomatic coronary heart disease, cardiac arrhythmia or myocardial infarction within the last 12 months.

7. Known HIV infection

8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, other serious uncontrolled concomitant disease, psychiatric illness/ social situation that would limit study compliance.

9. Known allergies to any component of the study drug

10. Lack of physical integrity of the upper gastrointestinal tract or those with malabsorption syndrome

11. Organ allografts

12. Known dihydropyrimidine dehydrogenase deficiency

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• Capecitabine
Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy. Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period.

Locations

Country	Name	City	State
Singapore	National University Hospital	Singapore

Sponsors (1)

Lead Sponsor	Collaborator
National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

References & Publications (2)

Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002 Jan;17(1):46-9. — View Citation

Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 2005 Dec;6(8):835-47. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the maximal tolerated dose (MTD) of capecitabine twice a day for two weeks followed by one week rest period (intermittent schedule) in patients with the advanced/ and or metastatic cancer based on TYMS genotype.		4 weeks	Yes
Secondary	Plasma concentrations of capecitabine and its metabolites	Pharmacokinetic sampling will be performed during cycle 1 on days 1 and 14 at the following time points: Baseline (predose), and 15 min, 30 min, 1 hr, 2 hr, 4 hr, 5 hr and 6 hr after dosing. Blood samples will be centrifuged at 1500 g and 4oC for 10 min and supernatant plasma removed and stored below -20oC until analysis. Plasma concentrations of capecitabine and its metabolites will be quantified by a validated liquid chromatography with mass-spectrometry detection (LC-MS-MS) method	3 weeks	No